Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed Tomography

Background This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by high-resolution peripheral quantitative computed tomography (HR-pQCT). Methods This was a one-year double-blind, randomized, placebo-controlled trial (NCT036238...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingzhao Jin, Isaac T Cheng, Ho So, Billy T Lai, Shirley K Ying, Kitty Y Kwok, James Griffith, Vivian Hung, Cheuk-Chun Szeto, Jack Jock-Wai Lee, Ling Qin, Lai-shan Tam
Format: Article
Language:English
Published: World Scientific Publishing 2024-01-01
Series:Journal of Clinical Rheumatology and Immunology
Online Access:https://www.worldscientific.com/doi/10.1142/S2661341724740572
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846169786316226560
author Yingzhao Jin
Isaac T Cheng
Ho So
Billy T Lai
Shirley K Ying
Kitty Y Kwok
James Griffith
Vivian Hung
Cheuk-Chun Szeto
Jack Jock-Wai Lee
Ling Qin
Lai-shan Tam
author_facet Yingzhao Jin
Isaac T Cheng
Ho So
Billy T Lai
Shirley K Ying
Kitty Y Kwok
James Griffith
Vivian Hung
Cheuk-Chun Szeto
Jack Jock-Wai Lee
Ling Qin
Lai-shan Tam
author_sort Yingzhao Jin
collection DOAJ
description Background This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by high-resolution peripheral quantitative computed tomography (HR-pQCT). Methods This was a one-year double-blind, randomized, placebo-controlled trial (NCT0362386740). Patients with erosion in the metacarpophalangeal joints (MCPJ) 2-4 were randomised in a 1:1 ratio to either the secukinumab or placebo group. HR-pQCT of the MCPJ 2-4 were performed at baseline, week-24 and 1-year. Progression of enthesiophyte were defined as changes in enthesiophyte volume exceeding smallest detectable change (SDC) (0.12mm3) or the identification of any new enthesiophyte. Partial repair of erosion was defined as a reduction in erosion volume greater than SDC (0.1mm3). Results Forty patients (age: 51.9± 13.4 years, 20 [50%] male) were recruited. Thirty-four patients who completed study treatment were included in the per-protocol analysis. The erosion volume at baseline, week-24 and week-48 revealed significant reduction in the secukinumab group while no differences in the placebo group (Figure-3A). There was a trend suggesting that fewer patients developed new-erosions in the secukinumab group (one-erosion in one-patient) compared to the placebo group (six-erosions in five-patients) (p=0.078) (Figure-3B). A significantly higher proportion of erosions with partial healing was observed in the secukinumab group compared with the placebo group [51%vs30%, p=0.029] (Figure-3C). Regarding enthesiophyte, a total of 25-enthesiophytes were identified in both the secukinumab and placebo groups at baseline. The enthesiophyte volume at baseline, week-24 and week-48 revealed significant differences in the secukinumab group while no differences in the placebo group (Figure-3D). While one (one-enthesiophyte in one-patient) and four-enthesiophytes (four-enthesiophytes in three-patients) were newly identified in the secukinumab group and placebo group respectively (Figure-3E), the proportion of enthesiophyte progression was numerically higher in the placebo group than the secukinumab group [40%vs16%, p=0.114] at week 48 (Figure-3F). GEE results showed that the odds ratio (OR) for enthesiophyte progression in the secukinumab group was 0.264 (95% CI: 0.080-0.878, p=0.030), while the OR for partial erosion healing in the secukinumab group was 2.816 (95% CI: 1.109 to 7.153, p=0.029), adjusting for tender-joint-counts. Conclusions Secukinumab demonstrates a potential benefit in facilitating partial erosion repair and preventing enthesiophyte progression in PsA.
format Article
id doaj-art-33ba4bf5b97747a5b24b0c04368af156
institution Kabale University
issn 2661-3417
2661-3425
language English
publishDate 2024-01-01
publisher World Scientific Publishing
record_format Article
series Journal of Clinical Rheumatology and Immunology
spelling doaj-art-33ba4bf5b97747a5b24b0c04368af1562024-11-12T08:27:23ZengWorld Scientific PublishingJournal of Clinical Rheumatology and Immunology2661-34172661-34252024-01-0124supp01828310.1142/S2661341724740572Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed TomographyYingzhao Jin0Isaac T Cheng1Ho So2Billy T Lai3Shirley K Ying4Kitty Y Kwok5James Griffith6Vivian Hung7Cheuk-Chun Szeto8Jack Jock-Wai Lee9Ling Qin10Lai-shan Tam11The Chinese University Of Hong Kong, Hong Kong, Hong Kong SARThe Chinese University Of Hong Kong, Hong Kong, Hong Kong SARThe Chinese University Of Hong Kong, Hong Kong, Hong Kong SARTseung Kwan O Hospital, Hong Kong, ChinaPrincess Margaret Hospital, Hong Kong, ChinaQueen Elizabeth Hospital, Hong Kong, ChinaDepartment of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong, ChinaDepartment of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, ChinaThe Chinese University Of Hong Kong, Hong Kong, Hong Kong SARDivision of Biostatistics, The Jockey Club School of Public Health & Primary Care, Hong Kong, ChinaDepartment of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, ChinaThe Chinese University Of Hong Kong, Hong Kong, Hong Kong SARBackground This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by high-resolution peripheral quantitative computed tomography (HR-pQCT). Methods This was a one-year double-blind, randomized, placebo-controlled trial (NCT0362386740). Patients with erosion in the metacarpophalangeal joints (MCPJ) 2-4 were randomised in a 1:1 ratio to either the secukinumab or placebo group. HR-pQCT of the MCPJ 2-4 were performed at baseline, week-24 and 1-year. Progression of enthesiophyte were defined as changes in enthesiophyte volume exceeding smallest detectable change (SDC) (0.12mm3) or the identification of any new enthesiophyte. Partial repair of erosion was defined as a reduction in erosion volume greater than SDC (0.1mm3). Results Forty patients (age: 51.9± 13.4 years, 20 [50%] male) were recruited. Thirty-four patients who completed study treatment were included in the per-protocol analysis. The erosion volume at baseline, week-24 and week-48 revealed significant reduction in the secukinumab group while no differences in the placebo group (Figure-3A). There was a trend suggesting that fewer patients developed new-erosions in the secukinumab group (one-erosion in one-patient) compared to the placebo group (six-erosions in five-patients) (p=0.078) (Figure-3B). A significantly higher proportion of erosions with partial healing was observed in the secukinumab group compared with the placebo group [51%vs30%, p=0.029] (Figure-3C). Regarding enthesiophyte, a total of 25-enthesiophytes were identified in both the secukinumab and placebo groups at baseline. The enthesiophyte volume at baseline, week-24 and week-48 revealed significant differences in the secukinumab group while no differences in the placebo group (Figure-3D). While one (one-enthesiophyte in one-patient) and four-enthesiophytes (four-enthesiophytes in three-patients) were newly identified in the secukinumab group and placebo group respectively (Figure-3E), the proportion of enthesiophyte progression was numerically higher in the placebo group than the secukinumab group [40%vs16%, p=0.114] at week 48 (Figure-3F). GEE results showed that the odds ratio (OR) for enthesiophyte progression in the secukinumab group was 0.264 (95% CI: 0.080-0.878, p=0.030), while the OR for partial erosion healing in the secukinumab group was 2.816 (95% CI: 1.109 to 7.153, p=0.029), adjusting for tender-joint-counts. Conclusions Secukinumab demonstrates a potential benefit in facilitating partial erosion repair and preventing enthesiophyte progression in PsA.https://www.worldscientific.com/doi/10.1142/S2661341724740572
spellingShingle Yingzhao Jin
Isaac T Cheng
Ho So
Billy T Lai
Shirley K Ying
Kitty Y Kwok
James Griffith
Vivian Hung
Cheuk-Chun Szeto
Jack Jock-Wai Lee
Ling Qin
Lai-shan Tam
Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed Tomography
Journal of Clinical Rheumatology and Immunology
title Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed Tomography
title_full Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed Tomography
title_fullStr Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed Tomography
title_full_unstemmed Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed Tomography
title_short Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis-A One-year Double-blind, Randomized, Placebo-controlled Trial Utilizing High-resolution Peripheral Quantitative Computed Tomography
title_sort effects of secukinumab on enthesiophyte and erosion progression in psoriatic arthritis a one year double blind randomized placebo controlled trial utilizing high resolution peripheral quantitative computed tomography
url https://www.worldscientific.com/doi/10.1142/S2661341724740572
work_keys_str_mv AT yingzhaojin effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT isaactcheng effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT hoso effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT billytlai effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT shirleykying effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT kittyykwok effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT jamesgriffith effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT vivianhung effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT cheukchunszeto effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT jackjockwailee effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT lingqin effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography
AT laishantam effectsofsecukinumabonenthesiophyteanderosionprogressioninpsoriaticarthritisaoneyeardoubleblindrandomizedplacebocontrolledtrialutilizinghighresolutionperipheralquantitativecomputedtomography